Conference Day One

7:30 Networking Breakfast & Conference Registration Sponsored By Sanofi Networking Breakfast & Conference Registration Sponsored By Sanofi

8:45 Chairperson's Opening Remarks Jeff Totten, Vice President Life Sciences Practice, Dean & Company Chairperson's Opening Remarks Jeff Totten Vice President Life Sciences Practice, Dean & Company Mr. Totten is a Vice President of Dean & Company and head of its Life Sciences practice. Prior to joining the firm, Mr. Totten was a Principal at Mercer Management Consulting (now Oliver Wyman), and one of the founders of its Life Sciences practice. Previously, Mr. Totten worked in Brand Management at the Procter & Gamble Company.Mr. Totten’s work has spanned corpor [read more]

9:00 Panel: Trends In Pharma M&A Activity Erin Lavelle, Executive Director, Amgen Strategy and Corporate Development, Amgen Incorperation Ellen Lubman, Group Director, Strategic Transactions Group, Bristol-Myers Squibb Company Richard Masterson, Jr., President & COO, Valeant International (Barbados) SRL Jon Norris, Managing Director, SVB Capital Matt Porzio, VP of Product Marketing , Intralinks Pharma continued to witness major M&A deals in 2010. And as the struggle to protect revenue loss against upcoming patent expirations continues, conditions are prime for the pace of M&A to increase in 2011. Emerging markets and new distribution channels are the focal points of many M&A strategies. This session will cover the drivers for the various M&A strategies, projections for competitive pricing and creative acquisitive deal structures like the contingent value rights (CVR) structure. Erin Lavelle Executive Director, Amgen Strategy and Corporate Development, Amgen Incorperation Ellen Lubman Group Director, Strategic Transactions Group, Bristol-Myers Squibb Company Ellen Lubman is a Group Director in the Strategy, Alliances and Transactions Group at Bristol-Myers Squibb. Ellen focuses on M&A execution and strategy, identification of new transaction opportunities, and initiation of “String of Pearls transactions, as well as spearheading novel business initiatives. Prior to joining Bristol-Myers Squibb, Ellen worked with Celtic Pharma, L.P., a [read more] Richard Masterson, Jr. President & COO, Valeant International (Barbados) SRL Rich Masterson is President of Valeant International (Barbados) SRL and Chariman of its Board. He leads Valeant’s wholly owned subsidiary in Barbados, which is the locus of the majority of the asset purchase transactions completed by the Company. He has more than twenty-two years of experience in the pharmaceutical industry spanning a broad range of commercial responsibilities in numerous therapeu [read more] Jon Norris Managing Director, SVB Capital Jon Norris is a managing director with SVB Capital's Venture Capital Relationship Management team, specializing in life sciences. Norris oversees strategic relationships with select life science venture capital firms on the West Coast, sourcing and advising on direct equity co-investment, limited partnership, and portfolio company banking and lending opportunities. In addition, he helps life scien [read more] Matt Porzio VP of Product Marketing , Intralinks Matthew Porzio, Vice President of Product Marketing, joined IntraLinks in August of 2003. He is responsible for driving the development and marketing of IntraLinks' Exchanges including virtual dealroom/dataroom solutions for the M&A and restructuring communities. Before joining IntraLinks, he was a senior associate at Metzler, a German advisory firm, where he focused on cross-borde [read more]

10:00 Panel: Timing The Deal – Finding The Balance Between Risk And Reward Milton Grannatt, VP & Head, Negotiations, Respiratory & New Growth Opportunities, Novartis Pharmaceuticals Corporation Jonathan Mow, VP of Business Development, Amylin Guy Van Meter, Senior Director, Head of Business Development, adimab Ben Bonifant, Senior Vice President and Practice Area Leader, Campbell Alliance All licensors in the biopharma industry share the challenge of timing the deal to balance the risk and financial reward. In this session,we'll hear from both in-licensors and out-licensors sharing their personal experiences of making decisions on timing the deal. The panelists will discuss trends in pharma licensing from the last year, identify market indicators for when a deal may occur and how to prepare for influencers beyond your control. Milton Grannatt VP & Head, Negotiations, Respiratory & New Growth Opportunities, Novartis Pharmaceuticals Corporation Milt Grannatt is Vice President and Head, Negotiations for Respiratory in Global Business Development and Licensing at Novartis. Prior to Novartis, he held senior positions at Sterling Winthrop and Lex Service, an acquisitive UK-based company. Dr. Grannatt has an extensive deal sheet. Jonathan Mow VP of Business Development, Amylin Jonathan Mow is Vice President, Business Development for Amylin Pharmaceuticals located in San Diego, CA since he joined the company in 2007. Prior to joining Amylin, Mr. Mow was Co-founder, Vice President, Commercial and Business Development, and Secretary of Corus Pharma, Inc. until their acquisition by Gilead Sciences in 2006. From 1997 to 2000, Mr. Mow led the Business Development efforts for [read more] Guy Van Meter Senior Director, Head of Business Development, adimab Guy Van Meter is Head of Business Development for Adimab, LLC, an antibody discovery company. In the first 2 years from platform launch, Mr. Van Meter has helped build Adimab into one of the most successful antibody platform companies in the industry, generating deals with Merck, Roche, Pfizer, Lilly, Novartis, Genentech, Novo Nordisk, BiogenIdec and other top pharma companies. Prior to Adimab, Mr [read more] Ben Bonifant Senior Vice President and Practice Area Leader, Campbell Alliance Ben Bonifant is the leader of Campbell Alliance’s Business Development practice. In that role, Mr. Bonifant assists leaders in large and small pharmaceutical and biotechnology companies on key licensing and acquisition initiatives. He also acts as a strategic advisor to venture capital and private equity decision makers. Prior to joining Campbell, Mr. Bonifant was a partner in the Strategy Practic [read more]

11:00 Refreshment Break & Networking Opportunity Hosted By: Sanofi Refreshment Break & Networking Opportunity

11:30 Panel: Innovative Deal Structures For 2012 And Beyond Brent Bankosky, Vice President Business Development, Tranzyme Pharma David Donabedian, VP Global New Deal Strategy & Development, ceedd, GSK Wael Fayad, VP Business Development, Forest Laboratories, Inc. Baruch Harris, VP, Strategy and Operations, Enlight Biosciences Jonathan MacQuitty, Ph.D., Partner, Abingworth Management Inc. Risk management of deals is by no means a new concept in pharmaceutical dealmaking. Option based deals and structured acquisitions have become standard deal making tools. But what can we learn from other industries using creative deal structures? This session will take a look outside the biopharma industry for examples of deal structures and will also explore where the biopharma industry is heading with innovative deal models. Brent Bankosky Vice President Business Development, Tranzyme Pharma Mr. Bankosky joined Tranzyme Pharma as Vice President, Business Development in August, 2011. Previously, Mr. Bankosky was employed by Takeda Pharmaceuticals International, Inc. as Senior Director, Global Licensing & Business Development where he was responsible for in-licensing and out-licensing of key programs across several therapeutic areas including Diabetes, Obesity, Cardiovas [read more] David Donabedian VP Global New Deal Strategy & Development, ceedd, GSK Dr. Donabedian is Vice President, Global New Deal Strategy and Development and is a member of the ceedd leadership team. In this role, he is accountable for setting the ceedd new deal portfolio strategy and composition and working closely with GSK worldwide business development to establish new alliances. Prior to this position, Dr. Donabedian was the Vice President of Strategic Alliances in GSK's [read more] Wael Fayad VP Business Development, Forest Laboratories, Inc. Wael has more than 17 years of experience in the pharmaceutical industry where he held positions of increasing responsibility in sales, marketing, new product development and business development. Wael joined Forest in 2001 and he currently heads the Business Development group responsible for all licensing and M&A activity. Prior to Forest, Wael worked at Schering Plough in Kenilwo [read more] Baruch Harris VP, Strategy and Operations, Enlight Biosciences Enlight Biosciences is a Boston-based venture creation firm, established in partnership with major pharmaceutical companies to develop breakthrough innovations that will fundamentally alter drug discovery and development. Dr. Harris manages Enlight’s day-to-day operations and is responsible for providing management support to Enlight’s portfolio companies. Prior to joining Enlight, Dr. Harris was [read more] Jonathan MacQuitty, Ph.D. Partner, Abingworth Management Inc. Dr. MacQuitty has headed up Abingworth’s West Coast office since 1999. Abingworth is a leading life science investor in both US and Europe having invested in over 100 companies with over $1.3B currently being managed. Before Abingworth, Dr. MacQuitty was CEO for 9 years of GenPharm International, a biotech firm he co-founded in 1988 to develop transgenic animal technology. Prior to GenPharm, he he [read more]

12:30 Case Study: Forest Laboratories Acquires Clinical Data Inc. Wael Fayad, VP Business Development, Forest Laboratories, Inc. Drew Fromkin, Former CEO Clinical Data , Clinical Data (Acquired By Forest Laboratories, Inc.) Case Study: Forest Laboratories Acquires Clinical Data Inc. Wael Fayad VP Business Development, Forest Laboratories, Inc. Wael has more than 17 years of experience in the pharmaceutical industry where he held positions of increasing responsibility in sales, marketing, new product development and business development. Wael joined Forest in 2001 and he currently heads the Business Development group responsible for all licensing and M&A activity. Prior to Forest, Wael worked at Schering Plough in Kenilwo [read more] Drew Fromkin Former CEO Clinical Data , Clinical Data (Acquired By Forest Laboratories, Inc.) Andrew J. Fromkin joined Clinical Data, Inc. on October 12, 2005 and was elected President, Chief Executive Officer, and Executive Director on May 12, 2006. Clinical Data, Inc. (CLDA) was rapidly transformed into a public pharmaceutical company developing first-in-class and best-in-category therapeutics, with a focus on advancing late-stage products and developing related companion diagnostics. On [read more]

1:00 Networking Lunch For All Conference Attendees Hosted By Sanofi Networking Lunch For All Conference Attendees Hosted By Sanofi

2:15 Panel: Partnering A Platform Technology Today When Companies Want A Drug Tomorrow Hemmie Chang, Chair, Licensing & Strategic Alliances Practice Group, Foley Hoag Phil Gutry, Principal, MPM Capital George Golumbeski, Senior Vice President Business Development, Celgene Corporation Kevin Skol, Director, Business Development, Isis Pharmaceuticals, Inc. In the current economic climate, platform deals have been taking a back seat to drug development. What are the factors a company considers in building a strategy around a technology platform in comparison to creating a product strategy? This session will discuss how to gain interest from partners and structure the deal. Hemmie Chang Chair, Licensing & Strategic Alliances Practice Group, Foley Hoag Ms. Hemmie Chang, Partner Foley Hoag LLP. Hemmie chairs Foley Hoag’s Licensing & Strategic Alliances Group where she focuses on complex collaboration and licensing transactions. She has over two decades of experience advising both pharmaceutical and emerging biotech companies, recently advising Translational Therapeutics in a BioWorld International Deal of the Week with Clavis Phar [read more] Phil Gutry Principal, MPM Capital Phil Gutry joined MPM's San Francisco office as a Principal in 2011. He previously worked for five years in Corporate Development at Gilead Sciences where he focused on M&A and licensing in antiviral, respiratory, and liver disease. His deal experience includes Gilead's acquisition of Arresto Biosciences and partnership with MicroDose Therapeutx. Prior to Gilead, Phil was a Princip [read more] George Golumbeski Senior Vice President Business Development, Celgene Corporation In a career spanning nearly 20 years, George has held senior positions in R&D and Business Development. In his most recent two positions, he has led business development functions at leading oncology companies. He has a strong record of closing significant in-licensing and M&A transactions. George is currently Senior Vice President of Business Development for Celgen [read more] Kevin Skol Director, Business Development, Isis Pharmaceuticals, Inc. Kevin Skol leads the business development activities at Isis Pharmaceuticals as the Director of Business Development. Kevin is primarily responsible for implementing Isis’ innovative partnering structures including its Preferred Partner Alliance model and Satellite Company strategy which now includes over a dozen technology and drug development collaborations. Prior to Isis, Kevin was a marketing [read more]

3:15 Panel: Diversifying Portfolios Outside Traditional Drug Development Roger Graben, SVP, Operations & Business Development, Kowa Pharmaceuticals America, Inc. James Hattersley, Vice President, Business Development, Sun Pharmaceuticals Industries Inc Brad Prosek, Senior Director of Corporate Development, Cubist Pharmaceuticals, Inc. Financial markets are giving higher valuations to more diversified companies. Many of the large pharmaceutical companies are diversifying away from patented drug development. In this session, we will discuss the variations in the strategies companies are taking to diversify including the shift into generics, consumer health and vaccines. Roger Graben SVP, Operations & Business Development, Kowa Pharmaceuticals America, Inc. Roger D. Graben, Ph.D., R.Ph. is Senior Vice President, Operations & Business Development, at Kowa Pharmaceuticals America (KPA) in Montgomery, AL. Dr. Graben is responsible for Business Development, Alliance Management, Quality Assurance, Pharmacovigilance, Regulatory Affairs, Trade, Distribution, Operations, Facilities, Fleet, and IT. Dr. Graben joined KPA in 2006 and has previou [read more] James Hattersley Vice President, Business Development, Sun Pharmaceuticals Industries Inc James Hattersley has over 22 years of successful leadership experience within biotechnology and pharmaceutical industries. From 1986 through 1995 Jim was responsible for R&D advancements in drug delivery at Alza Corp and Abbott Labs. From 1995 to present day 2011 Jim has led the execution of growth strategy at Sun Pharmaceutical Industries, in addition to several transactions of si [read more] Brad Prosek Senior Director of Corporate Development, Cubist Pharmaceuticals, Inc. Brad Prosek currently serves as Senior Director, Corporate Development for Cubist Pharmaceuticals, Inc. In this role, Brad sources and structures transactions supporting Cubist’s pipeline buildout. Previously at Cubist, Brad started and led the Market Access group, a sales organization focused on developing non-hospital markets for the company’s flagship product CUBICIN (daptomycin for injection). [read more]

4:15 Refreshment Break & Networking Opportunity Refreshment Break & Networking Opportunity

4:45 Bristol-Myers Squibb Completes Acquisition of Amira Pharmaceuticals Hari Kumar, Ph.D., Chief Executive Officer, Panmira Pharmaceuticals Ellen Lubman, Group Director, Strategic Transactions Group, Bristol-Myers Squibb Company Hot transaction….fresh off the presses.Big pharma. Small biotech. Strategic fit. Innovative structure. 6 weeks from first communication to announcement of acquisition. Wouldn't it be great if all big pharma M&A could be this way?Come hear the story of Bristol Myers Squibb's acquisition of Amira Pharmaceuticals, which was announced on July 21 after a fist diligence discussion in early June. The acquisition's completion was just announced on September 8. Hari Kumar, Ph.D. Chief Executive Officer, Panmira Pharmaceuticals Hari Kumar brings to Panmira almost 20 years of big pharmaceutical experience. Hari spent a total of 17 years at Hoffmann-La Roche, where he began his career in basic research, moved to sales and marketing, lifecycle management, and finally, business development. In 1996, Hari moved to Eisai Ltd, where he served as the company’s European Marketing Director before returning to Roche in 1999.During [read more] Ellen Lubman Group Director, Strategic Transactions Group, Bristol-Myers Squibb Company Ellen Lubman is a Group Director in the Strategy, Alliances and Transactions Group at Bristol-Myers Squibb. Ellen focuses on M&A execution and strategy, identification of new transaction opportunities, and initiation of “String of Pearls transactions, as well as spearheading novel business initiatives. Prior to joining Bristol-Myers Squibb, Ellen worked with Celtic Pharma, L.P., a [read more]

5:30 Cocktail Reception For All Attendees Cocktail Reception For All Attendees